Ufp Technologies (UFPT) AI Stock Analysis

• Market Cap: $1.49B
• Dividend Yield: N/A
• Average Volume (3M): 109.77K
• Price to Earnings (P/E): 22.0
• Beta (1Y): 1.35
• Revenue Growth: 40.98%
• EPS Growth: 34.80%
• Country: US
• Employees: 4,146
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.50
• Shares Outstanding: 7,711,126
• 10 Day Avg. Volume: 133,172
• 30 Day Avg. Volume: 109,765
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.38
• Enterprise Value/Revenue: 3.77
• Enterprise Value/Gross Profit: 13.00
• Enterprise Value/Ebitda: 19.52
• 1Y Price Target: $266.50
• Price Target Upside: 40.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 73 Outperform
• Price Target: $244.00 ▲(28.39% Upside)

UFPT's overall stock score reflects strong financial performance and strategic growth initiatives in the medical sector. However, technical indicators suggest bearish momentum, and labor challenges present operational risks. The company's moderate valuation and strategic acquisitions provide a balanced outlook.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand and effective market strategies, supporting long-term business expansion and market penetration.

Strategic Acquisitions

Acquisitions enhance capabilities and synergies, positioning the company for growth in high-barrier sectors, strengthening competitive advantage.

Medical Business Expansion

Expansion in the medical sector diversifies revenue streams and capitalizes on high-growth markets, enhancing long-term stability and profitability.

Negative Factors

Labor Turnover Challenges

Labor challenges can disrupt operations and increase costs, affecting efficiency and margins, posing risks to sustained operational performance.

Backlog and Manufacturing Inefficiency

Manufacturing inefficiencies can lead to delayed deliveries and lost revenue, impacting customer satisfaction and long-term business relationships.

Advanced Components Business Decline

Decline in non-medical segments may limit diversification and revenue stability, increasing reliance on the medical sector for growth.

Ufp Technologies Business Overview & Revenue Model

Company Description

UFP Technologies, Inc. designs and custom manufactures components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics primarily for the medical market. Its single-use and single-patient devices and components are used in a range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging. The company also provides engineered products and components to customers in the automotive, aerospace and defense, consumer, electronics, and industrial markets, which are applied in military uniform and gear components, automotive interior trim, athletic padding, environmentally protective packaging, air filtration, abrasive nail files, and protective cases and inserts. It markets and sells its products in the United States principally through a direct sales force, as well as independent manufacturer representatives. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

How the Company Makes Money

Ufp Technologies generates revenue primarily through the sale of its packaging products and engineered materials. The company's revenue model is centered around providing customized solutions that meet specific customer requirements, which allows it to charge premium prices for its products. Key revenue streams include direct sales to original equipment manufacturers (OEMs), distribution partnerships, and government contracts. Additionally, Ufp Technologies benefits from long-term relationships with clients in various industries, which provide stable revenue through repeat business and contracts. The company also invests in research and development to create innovative products that capture new market opportunities, further enhancing its earning potential.

Ufp Technologies Financial Statement Overview

Summary

UFPT exhibits strong financial performance with robust revenue and profit growth, solid profitability margins, and a stable balance sheet with low leverage. Effective cash flow management further strengthens its financial health, positioning it well for future growth in the medical devices industry.

Income Statement

UFPT has demonstrated strong revenue growth with a significant increase from $400.1M in 2023 to $547.6M in TTM, resulting in a revenue growth rate of 8.56%. The gross profit margin stands at 28.99%, indicating effective cost management. The net profit margin improved to 11.59%, reflecting enhanced operational efficiency. Both EBIT and EBITDA margins are robust at 16.31% and 18.47% respectively, showcasing strong profitability.

Balance Sheet

The company maintains a solid financial position with a debt-to-equity ratio of 0.046, indicating low leverage. The return on equity is impressive at 17.6%, reflecting high efficiency in using shareholder equity to generate profits. An equity ratio of 56.13% suggests a strong equity base and financial stability.

Cash Flow

UFPT's free cash flow growth rate is 3.64%, demonstrating positive cash generation. The operating cash flow to net income ratio is 1.1, indicating healthy cash generation relative to income. The free cash flow to net income ratio stands at 0.93, confirming efficient cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	547.56M	504.42M	400.07M	353.79M	206.32M	179.37M
Gross Profit	158.76M	146.69M	112.22M	90.26M	51.11M	44.68M
EBITDA	105.74M	95.80M	68.95M	56.35M	30.04M	25.46M
Net Income	63.47M	58.98M	44.92M	41.79M	15.89M	13.37M
Balance Sheet
Total Assets	642.64M	629.00M	404.14M	377.54M	334.13M	203.20M
Cash, Cash Equivalents and Short-Term Investments	14.03M	13.45M	5.26M	4.45M	11.12M	24.23M
Total Debt	198.54M	206.03M	46.04M	55.00M	84.36M	2.21M
Total Liabilities	281.97M	286.24M	118.05M	140.00M	139.69M	26.31M
Stockholders Equity	360.67M	342.76M	286.09M	237.54M	194.45M	176.89M
Cash Flow
Free Cash Flow	59.01M	56.94M	30.84M	3.96M	8.90M	20.67M
Operating Cash Flow	69.75M	66.59M	41.33M	17.74M	14.29M	25.04M
Investing Cash Flow	-211.25M	-210.16M	-10.49M	1.29M	-101.46M	-4.26M
Financing Cash Flow	144.41M	152.39M	-30.02M	-25.89M	74.05M	-285.00K

Ufp Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 190.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UFPT, the sentiment is Negative. The current price of 190.04 is below the 20-day moving average (MA) of 202.26, below the 50-day MA of 216.06, and below the 200-day MA of 231.86, indicating a bearish trend. The MACD of -6.47 indicates Positive momentum. The RSI at 33.75 is Neutral, neither overbought nor oversold. The STOCH value of 24.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UFPT.

Ufp Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CNMD	74 Outperform	1.50B	13.70	10.99%	1.74%	4.02%	11.32%
UFPT	73 Outperform	$1.49B	22.03	19.29%	―	40.98%	34.80%
AHCO	63 Neutral	1.21B	16.32	5.15%	―	-0.61%	―
SIBN	63 Neutral	613.46M	-25.12	-18.51%	―	22.93%	43.83%
AORT	55 Neutral	1.93B	-94.07	-4.27%	―	7.44%	-109.83%
IART	47 Neutral	1.08B	-2.02	-48.20%	―	3.53%	-2309.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Ufp Technologies Corporate Events

UFP Technologies Highlights Strategic Focus in Investor Update

UFP Technologies has released updated presentation materials for investor meetings, highlighting its strategic focus on the medical device industry. The company emphasizes its innovative process from design to delivery, aiming to strengthen customer relationships and expand in high-margin markets. The presentation outlines the company’s growth strategies, including shifting its business to higher-margin opportunities and expanding its presence in various markets such as medical, aerospace, and defense. These updates are expected to enhance UFP Technologies’ market positioning and operational efficiency, potentially impacting stakeholders positively.

UFP Technologies Acquires UNIPEC and TPI for Expansion

On July 17, 2025, UFP Technologies announced the acquisition of UNIPEC and TPI, expanding its capabilities in the medical device market. UNIPEC, based in Rockville, Maryland, specializes in precision thermoformed and heat-sealed polymer components for implantable medical devices, enhancing UFP’s thin film platform. TPI, located in Anasco, Puerto Rico, manufactures precision thermoplastic injection-molded components, strengthening UFP’s thermoplastic molding capabilities. These acquisitions align with UFP’s strategy to grow in high-growth, high-barrier sectors, providing unique technologies and expertise that enhance partnerships with leading medical device OEMs.

UFP Technologies Highlights Strategic Focus on Medical Market

UFP Technologies has released updated presentation materials for investor meetings, highlighting their strategic focus on expanding in the medical device market. The company emphasizes its expertise in design, materials, and global manufacturing, aiming to shift its business towards higher-margin opportunities and expand its presence in the medical, aerospace, defense, and other markets. This move is expected to strengthen UFP’s market positioning and enhance its growth potential, although investors are cautioned about the risks and uncertainties associated with forward-looking statements.

UFP Technologies Holds Annual Stockholders Meeting

On June 4, 2025, UFP Technologies held its Annual Meeting of Stockholders where several key proposals were voted on. The stockholders elected seven directors to serve until the 2026 Annual Meeting, approved executive compensation, decided on the frequency of future votes on executive compensation, and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for 2025.